Levosimendan as a "Bridge to Optimization" in Patients with Advanced Heart Failure with Reduced Ejection-A Single-Center Study.

导出 LinkOut

翻译打印收藏纠错

作者： Daniele,Masarone ^[1] ; Michelle M,Kittleson ^[2] ; Maria L,Martucci ^[1] ; Fabio,Valente ^[1] ; Rita,Gravino ^[1] ; Marina,Verrengia ^[1] ; Ernesto,Ammendola ^[1] ; Carla,Contaldi ^[1] ; Vito,Di Palma ^[1] ; Angelo,Caiazzo ^[3] ; Andrea,Petraio ^[3] ; Piero,Pollesello ^[4] ; Giuseppe,Pacileo ^[1]

作者单位： Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital Naples, 80131 Naples, Italy. ^[1] Department of Cardiology, Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA 90048, USA. ^[2] Heart Transplant Unit, Department of Cardiac Surgery and Transplant, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. ^[3] Critical Care, Orion Pharma, 02101 Espoo, Finland. ^[4]

关键词 advanced heart failure disease modifier drugs heart failure reduced ejection fraction levosimendan

DOI 10.3390/jcm11144227

PMID 35887992

发布时间 2023-03-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of clinical medicine

2022年11卷14期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Levosimendan as a "Bridge to Optimization" in Patients with Advanced Heart Failure with Reduced Ejection-A Single-Center Study.

Journal of clinical medicine

相似文献

Journal of clinical medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Levosimendan as a "Bridge to Optimization" in Patients with Advanced Heart Failure with Reduced Ejection-A Single-Center Study.

Journal of clinical medicine

相似文献

Journal of clinical medicine

相关期刊

检索历史清除